Vélez Ramón, Turesson Ingemar, Landgren Ola, Kristinsson Sigurdur Y, Cuzick Jack
Department of Medicine, Section on General Internal Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
Department of Hematology, Skåne University Hospital, Malmö, Sweden.
BMJ Open. 2016 Jan 21;6(1):e009584. doi: 10.1136/bmjopen-2015-009584.
The increased incidence of multiple myeloma (MM) across China and East Asia stimulated us to examine the current rates in Great Britain, where rates increased dramatically in the second half of the 20th century. However, rates have been stable and high during this period in Malmö, Sweden, where there is a keen interest in MM. We thus assessed recent changes in MM incidence in Great Britain, Sweden overall, and Malmö, Sweden, and examined how these changes might explain recent reports of increased MM incidence across Asia.
Estimation of MM incidence for Great Britain, Sweden overall, and Malmö, Sweden.
MM incidence data for Great Britain (1975-2009) were obtained from Cancer Research UK and for Sweden (1970-2009) from the Swedish Cancer Registry. MM incidence data from Malmö, Sweden, were available from 1950 to 2012.
Age-specific incidence of MM in Great Britain, Sweden overall, and Malmö, Sweden.
MM incidence in Great Britain, Sweden overall, and Malmö increased progressively with age, even among the oldest group. The MM age-adjusted incidence (European standard population) increased by 69% from 1975-1979 to 2005-2009 in Great Britain, from 3.2/100,000 to 5.4/100,000. The largest increases occurred among those 70-79 years of age, for whom rates increased from 17.9/100,000 to 33.6/100,000; reflecting an increase of 69%. During this same period, the age-adjusted incidence (European stand population) in Sweden overall remained stable, at approximately 4.7/100,000.
MM age-specific incidence is now similar in Great Britain, Sweden overall, and Malmö. We believe this is a result of improvements in case ascertainment in Great Britain, particularly among the elderly. Similar changes can be predicted to occur across Asia as improved access to healthcare contributes to better diagnosis of MM.
中国和东亚多发性骨髓瘤(MM)发病率的上升促使我们研究英国的当前发病率情况,英国的发病率在20世纪后半叶急剧上升。然而,在此期间瑞典马尔默的发病率一直稳定且居高不下,当地对MM有着浓厚的研究兴趣。因此,我们评估了英国、瑞典整体以及瑞典马尔默MM发病率的近期变化,并研究这些变化如何解释近期亚洲MM发病率上升的报道。
对英国、瑞典整体以及瑞典马尔默的MM发病率进行估算。
英国(1975 - 2009年)的MM发病率数据来自英国癌症研究中心,瑞典(1970 - 2009年)的数据来自瑞典癌症登记处。瑞典马尔默的MM发病率数据可追溯至1950年至2012年。
英国、瑞典整体以及瑞典马尔默按年龄划分的MM发病率。
英国、瑞典整体以及马尔默的MM发病率均随年龄增长而逐步上升,即使在最年长的人群中也是如此。英国经年龄调整后的MM发病率(欧洲标准人口)从1975 - 1979年的3.2/10万增至2005 - 2009年的5.4/10万,增幅为69%。增幅最大的是70 - 79岁人群,其发病率从17.9/10万增至33.6/10万,增幅为69%。同期,瑞典整体经年龄调整后的发病率(欧洲标准人口)保持稳定,约为4.7/10万。
英国、瑞典整体以及马尔默按年龄划分的MM发病率目前相似。我们认为这是英国病例确诊情况改善的结果,尤其是在老年人中。随着亚洲医疗保健可及性提高有助于MM的更好诊断,预计亚洲也会出现类似变化。